Clinical and pharmacological group: & nbsp

Gastroprotectors

Included in the formulation
  • Vikanol® Life
    pills inwards 
    NGO Farmvilar, OOO     Russia
  • ATOLL, LLC     Russia
  • ATOLL, LLC     Russia
  • Vitrinol
    pills inwards 
  • De-Nol®
    pills inwards 
    Astellas Farma Europe BV     Netherlands
  • Novobismol
    pills inwards 
  • Escape®
    pills inwards 
    OTISIFARM, OJSC     Russia
  • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    ONLS

    Minimal chemist's assortment

    АТХ:

    A.02.B.X.05   Bismuth tricalcium dicitrate

    Pharmacodynamics:

    Antiulcer agent with bactericidal activity against Helicobacter pylori. It also has an anti-inflammatory and astringent effect. In the acidic environment of the stomach forms insoluble bismuth oxychloride and citrate, and also chelate compounds are formed with the protein substrate in the form of a protective film on the surface of ulcers and erosions. Increasing the synthesis of prostaglandin E, the formation of mucus and the secretion of bicarbonate, stimulates the activity of cytoprotective mechanisms, increases the stability of the mucous membrane of the gastrointestinal tract to the effects of pepsin, hydrochloric acid (hydrochloric acid)enzymes and bile salts. It leads to the accumulation of the epidermal growth factor in the defect area. Reduces the activity of pepsin and pepsinogen.

    Pharmacokinetics:Bismuth tricalcium dicitrate is practically not absorbed from gastrointestinal tract. However, a small amount of bismuth can enter the systemic circulation. It is excreted mainly with feces. An insignificant amount of bismuth, which enters the plasma, is excreted by the kidneys.
    Indications:

    Peptic ulcer of the stomach and duodenum in the phase of exacerbation (including associated with Helicobacter pylori); chronic gastritis and gastroduodenitis in the phase of exacerbation (including associated with Helicobacter pylori); irritable bowel syndrome, mainly with symptoms of diarrhea; functional dyspepsia, not associated with organic diseases of the gastrointestinal tract.

    XI.K20-K31.K26   Duodenal ulcer

    XI.K20-K31.K25   Stomach ulcer

    XI.K20-K31.K29   Gastritis and duodenitis

    XI.K20-K31.K30   Dyspepsia

    XI.K55-K63.K58   Irritable Bowel Syndrome

    Contraindications:

    Severe renal dysfunction, pregnancy, lactation, hypersensitivity to bismuth tricalium dicitrate.

    Carefully:

    Do not use prolonged use of large doses. Within 30 minutes before and after taking it is necessary to refrain from drinks (in t.ch. milk, fruit and fruit juices), solid food, antacids. During therapy, do not consume alcohol.

    Pregnancy and lactation:

    Contraindicated in pregnancy and lactation (breastfeeding). Category by Food and Drug Administration (US Food and Drug Administration) not determined.

    Dosing and Administration:

    Adults and children older than 4 years - inside 2-4 times a day for 30 minutes before meals. The dose depends on the age of the patient.

    The course of treatment is 4-8 weeks. For the next 8 weeks, do not take drugs containing bismuth.

    For eradication Helicobacter pylori it is advisable to use bismuth tricalium dicitrate in combination with antibacterial drugs with anti-Helicobacter activity.

    Side effects:

    From the digestive system: transient effects are possible - nausea, vomiting, frequent stools, constipation.

    Dermatological reactions: skin rash, itching.

    From the central nervous system: with long-term use in high doses - encephalopathy associated with the accumulation of bismuth in central nervous system.

    Overdose:

    Symptoms: with frequent administration of large doses, it is possible to develop renal failure.

    Treatment: gastric lavage, the appointment of activated charcoal and saline laxatives, symptomatic therapy. Patients with impaired renal function, accompanied by a high level of bismuth in the plasma, enter the SH-containing complexing agents - dimercaptosuccinic and dimercaptopropanesulfonic acids. In case of severe renal failure, hemodialysis is performed.

    Interaction:

    Bismuth tricalcium dicitrate reduces the absorption of tetracycline.

    Special instructions:

    Do not use for more than 8 weeks.

    During treatment it is not recommended to exceed the established daily doses for adults and children.

    At the end of the course treatment at recommended doses, the concentration of active substance in the blood plasma does not exceed 3-58 μg / l, and intoxication is observed only at a concentration of more than 100 μg / l.

    Against the background of application, it is possible to stain the feces black due to the formation of bismuth sulphide. Sometimes there is a slight darkening of the tongue.

    Instructions
    Up